These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. [Treatment modification in multiple sclerosis: classifications, alternatives, and the outcomes]. Cendrowski W Neurol Neurochir Pol; 2007; 41(4):365-8. PubMed ID: 18027457 [No Abstract] [Full Text] [Related]
25. New Approaches to the Diagnosis, Clinical Course, and Goals of Therapy in Multiple Sclerosis and Related Disorders. Krieger SC Continuum (Minneap Minn); 2016 Jun; 22(3):723-9. PubMed ID: 27261678 [TBL] [Abstract][Full Text] [Related]
26. Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. Capello E; Saccardi R; Murialdo A; Gualandi F; Pagliai F; Bacigalupo A; Marmont A; Uccelli A; Inglese M; Bruzzi P; Sormani MP; Cocco E; Meucci G; Massacesi L; Bertolotto A; Lugaresi A; Merelli E; Solari A; Filippi M; Mancardi GL; Neurol Sci; 2005 Dec; 26 Suppl 4():S200-3. PubMed ID: 16388358 [TBL] [Abstract][Full Text] [Related]
28. Immune-based therapy of multiple sclerosis. Kaufman MD N C Med J; 1995 Aug; 56(8):379-84. PubMed ID: 7566191 [No Abstract] [Full Text] [Related]
29. Immunological basis for the therapy of multiple sclerosis. Hohlfeld R Acta Neurol Belg; 1999 Mar; 99(1):40-3. PubMed ID: 10218091 [TBL] [Abstract][Full Text] [Related]
30. Spreading of autoimmunity from central to peripheral myelin: two cases of clinical association between multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. Falcone M; Scalise A; Minisci C; Romito D; Cancelli I; Gigli GL Neurol Sci; 2006 Apr; 27(1):58-62. PubMed ID: 16688601 [TBL] [Abstract][Full Text] [Related]
32. The immunopathogenesis of multiple sclerosis. A survey of recent advances and implications for future therapy. Kieseier BC; Archelos JJ; Storch M; Gold R; Hartung HP Wien Klin Wochenschr; 1999 Sep; 111(17):728-37. PubMed ID: 10526397 [TBL] [Abstract][Full Text] [Related]
33. Not every patient with multiple sclerosis should be treated at time of diagnosis. Pittock SJ; Weinshenker BG; Noseworthy JH; Lucchinetti CF; Keegan M; Wingerchuk DM; Carter J; Shuster E; Rodriguez M Arch Neurol; 2006 Apr; 63(4):611-4. PubMed ID: 16606780 [No Abstract] [Full Text] [Related]
34. Current and emerging treatment of multiple sclerosis. Hart FM; Bainbridge J Am J Manag Care; 2016 Jun; 22(6 Suppl):s159-70. PubMed ID: 27356025 [TBL] [Abstract][Full Text] [Related]
35. Current immune therapies of autoimmune disease of the nervous system with special emphasis to multiple sclerosis. Vass K Curr Pharm Des; 2012; 18(29):4513-7. PubMed ID: 22612753 [TBL] [Abstract][Full Text] [Related]
36. Acute tumefactive demyelinating lesions in a pediatric patient with known diagnosis of multiple sclerosis: review of the literature and treatment proposal. Dastgir J; DiMario FJ J Child Neurol; 2009 Apr; 24(4):431-7. PubMed ID: 19189932 [TBL] [Abstract][Full Text] [Related]
37. Combination therapy for multiple sclerosis: the treatment strategy of the future? Weinstock-Guttman B; Bakshi R CNS Drugs; 2004; 18(12):777-92. PubMed ID: 15377168 [TBL] [Abstract][Full Text] [Related]
38. Rationale for the use of mitoxantrone in multiple sclerosis. Edan G; Morrissey S; Le Page E J Neurol Sci; 2004 Aug; 223(1):35-9. PubMed ID: 15261558 [TBL] [Abstract][Full Text] [Related]